HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jamie Honeychurch Selected Research

DSR-29133

3/2016Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jamie Honeychurch Research Topics

Disease

26Neoplasms (Cancer)
01/2022 - 08/2003
8Lymphoma (Lymphomas)
01/2016 - 08/2003
4B-Cell Lymphoma (Lymphoma, B Cell)
01/2013 - 08/2003
3Melanoma (Melanoma, Malignant)
02/2019 - 06/2015
2Colorectal Neoplasms (Colorectal Cancer)
03/2016 - 08/2014
2Kidney Neoplasms (Kidney Cancer)
03/2016 - 06/2015
2Leukemia
04/2012 - 08/2009
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/2012 - 08/2009
1Inflammation (Inflammations)
01/2022
1Bites and Stings (Sting)
09/2020
1Prostatic Neoplasms (Prostate Cancer)
09/2020
1Necrosis
01/2020
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2018
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2016
1Osteosarcoma (Osteogenic Sarcoma)
03/2016
1Head and Neck Neoplasms (Head and Neck Cancer)
06/2015
1Fibrosarcoma
08/2014
1Neoplasm Metastasis (Metastasis)
08/2014
1Hematologic Neoplasms (Hematological Malignancy)
02/2007
1Infections
11/2005

Drug/Important Bio-Agent (IBA)

11Monoclonal AntibodiesIBA
01/2016 - 08/2003
3Biomarkers (Surrogate Marker)IBA
01/2020 - 10/2014
3Toll-Like Receptor 7IBA
03/2016 - 01/2013
3AntigensIBA
01/2016 - 02/2007
2Biological ProductsIBA
01/2020 - 06/2015
2AntibodiesIBA
06/2015 - 02/2007
2Rituximab (Mabthera)FDA Link
10/2014 - 04/2011
2obinutuzumabIBA
10/2014 - 04/2012
2Neoplasm Antigens (Tumor Antigens)IBA
08/2014 - 08/2003
1InterferonsIBA
09/2020
1RNA (Ribonucleic Acid)IBA
09/2020
1Toll-Like Receptor AgonistsIBA
01/2020
1Doxycycline (Periostat)FDA LinkGeneric
02/2019
1Caspase 3 (Caspase-3)IBA
02/2019
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
03/2016
1DSR-29133IBA
03/2016
1LigandsIBA
06/2015
1IpilimumabIBA
06/2015
1Death Domain ReceptorsIBA
06/2015
1CTLA-4 AntigenIBA
06/2015
1VaccinesIBA
10/2014
1Therapeutic UsesIBA
08/2014
1DSR-6434IBA
08/2014
1Imiquimod (Aldara)FDA LinkGeneric
08/2014
1Clodronic Acid (Clodronate)IBA
09/2013
1Liposomes (Liposome)IBA
09/2013
1Reactive Oxygen Species (Oxygen Radicals)IBA
04/2012
1NADPH Oxidases (NAD(P)H oxidase)IBA
04/2012
1HLA-DR Antigens (HLA-DR)IBA
08/2009
1Antiviral Agents (Antivirals)IBA
11/2005
1Pharmaceutical PreparationsIBA
08/2005
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2005

Therapy/Procedure

14Radiotherapy
01/2022 - 01/2013
14Therapeutics
01/2022 - 08/2003
6Immunotherapy
01/2022 - 08/2005
2Intravenous Administration
03/2016 - 01/2013
2Radioimmunotherapy
02/2007 - 02/2004